Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2Phase 2 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Conditions

Breast Neoplasms 1931Neoplasms 1385Carcinoma, Non-Small-Cell Lung 1324Prostatic Neoplasms 1070Multiple Myeloma 855Leukemia, Myeloid, Acute 759Neoplasm Metastasis 691Colorectal Neoplasms 676Melanoma 666Lung Neoplasms 665Lymphoma 655Leukemia 591Lymphoma, Non-Hodgkin 587Leukemia, Lymphocytic, Chronic, B-Cell 529Ovarian Neoplasms 517Pancreatic Neoplasms 493Precursor Cell Lymphoblastic Leukemia-Lymphoma 471Recurrence 466Myelodysplastic Syndromes 421Lymphoma, Follicular 407Head and Neck Neoplasms 401Glioblastoma 376Carcinoma, Renal Cell 375Lymphoma, Large B-Cell, Diffuse 372Brain Neoplasms 370Hodgkin Disease 352Carcinoma, Hepatocellular 324Squamous Cell Carcinoma of Head and Neck 323Lymphoma, Mantle-Cell 302Sarcoma 281

Interventions

pembrolizumab 2MLN 8237 2pemigatinib 1liposomal doxorubicin 1cabiralizumab 1Nivolumab 1AZD7648 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Has results × Advanced Malignancies × Clear all
NCT04837196 2025-08-08

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Astellas Pharma Inc

Phase 1/2 Completed
24 enrolled 47 charts

Advanced Malignancies

NCT04949191 2024-09-19

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Incyte Corporation

Phase 2 Terminated
10 enrolled 9 charts

Advanced Malignancies

NCT03907969 2024-02-06

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

AstraZeneca

Phase 1/2 Completed
30 enrolled 17 charts

Advanced Malignancies

NCT03158272 2020-12-21

A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

Bristol-Myers Squibb

Phase 1 Completed
19 enrolled 26 charts

Advanced Malignancies

NCT00651664 2019-03-15

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

Takeda

Phase 1 Completed
59 enrolled 51 charts

Advanced Malignancies

NCT00500903 2019-03-14

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

Takeda

Phase 1 Completed
87 enrolled 68 charts

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡